Company | Ticker | Business Description | Underwriters | Offer Date |
---|---|---|---|---|
Beam Therapeutics> | BEAM> | Preclinical biotech developing therapies based on single-base gene editing. | JP Morgan Jefferies |
02/05/20 |
Caribou Biosciences> | CRBU> | Phase 1 biotech developing gene edited cell therapies for multiple cancers. | BofA Sec. Citi |
07/22/21 |
Cibus> | CBUS> | Developing gene-edited crop traits for the global seed industry. | Morgan Stanley BofA Sec. |
Withdrawn |
Foxit Software> | |
|||
LENZ Therapeutics> | LENZ> | Phase 1/2-ready biotech developing gene editing therapies for sickle cell and other diseases. | Morgan Stanley BofA Sec. |
06/24/21 |
Metagenomi> | MGX> | Preclinical biotech using metagenomics-derived genome editing. | JP Morgan Jefferies |
02/08/24 |
Prime Medicine> | PRME> | Preclinical biotech developing novel gene editing therapies for various diseases. | JP Morgan Goldman |
10/19/22 |
Thai Credit Bank> | |
|||
Verve Therapeutics> | VERV> | Preclinical biotech developing single-course gene editing therapies for cardiovascular disease. | JP Morgan Jefferies |
06/16/21 |
News Results for edit |
---|